Team’s FRM 2022 – G Gorochov
Guy Gorochov’s team has been awarded the Equipe FRM 2022 label for the project «Study and manipulation of host-microbiota mutualism regulated by immunoglobulin A»
“Exploring the microbiome to displace multi-drug resistant Enterobacteria from the gut”
« Identification of key components of proteostasis regulation for diagnosis and targeting of inflammatory diseases and cancer »
“Lower disease activity but higher risk of severe COVID- 19 and herpes zoster in patients with systemic lupus erythematosus with pre-existing autoantibodies neutralising IFN-α”
Trans-cellular tunnels induced by the fungal pathogen Candida albicans facilitate invasion through successive epithelial cells without host damage
Trans-cellular tunnels induced by the fungal pathogen Candida albicans facilitate invasion through successive epithelial cells without host damage.
« Malaria, asplenia : a story of sensing, swelling, sickling & pitting »
« Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses »
The effectiveness of a vaccine against #HIV
Dr behazine combadière, a lead investigator at the centre for immunology and infectious diseases @inserm is working on predicting the effectiveness of a vaccine against #hiv which is concurrently advancing the #covidvaccine development research.
Vaccine responses against SARS-CoV-2 variants examined in people with lupus
The majority of people with systemic lupus erythematosus (SLE) who respond to messenger (m)RNA COVID-19 vaccines also generate an antibody response against emerging SARS-CoV-2 variants, albeit with reduced neutralizing activity against variants bearing the E484K mutation, researchers report.
A personalized precision medicine approach is needed to treat Covid-19 as more than one type of “Cytokine storm” is induced by SARS-CoV-2
The severe form of Covid-19 is known to be associated with the excessive elevation of many cytokines, a condition termed “cytokine storm”. Therapy with biological agents intended to block these cytokines, for example anti-interleukin-6 or anti-interleukin-1 antibodies, was already tried, albeit with a limited success.